摘要
目的探讨黑骨藤追风活络胶囊联合甲氨蝶呤治疗类风湿性关节炎的疗效与安全性。方法选择2017年7月—2018年10月收治的类风湿性关节炎患者92例为研究对象,应用随机数字表法将分为参照组与联合组,每组各46例。参照组采用洛索洛芬钠和甲氨蝶呤治疗,联合组在参照组基础上加用黑骨藤追风活络胶囊。比较2组病情恢复情况,治疗4周和治疗16周时的ACR20、ACR50达标率以及不良反应。结果联合组病情好转率为80.43%,明显高于参照组,差异有统计学意义(P<0.05)。联合组治疗4周的ACR20达标率及治疗16周的ACR50达标率均高于参照组,差异有统计学意义(P<0.05)。2组患者均未出现严重的不良反应。结论对类风湿性关节炎患者给予黑骨藤追风活络胶囊联合甲氨蝶呤能够有效控制病情进展,改善症状,且安全可靠,值得推广。
Objective To investigate and analyze the efficacy and safety of Heiguteng Zhuifenghuoluo Capsule combined with methotrexate in the treatment of rheumatoid arthritis. Methods 92 patients with rheumatoid arthritis admitted from July 2017 to October 2018 were selected as the study subjects. All patients were divided into control group and combined group by random number table method,46 cases in each group. The control group was treated with loxoprofen sodium and methotrexate,and the combined group was treated with Heiguteng Zhuifenghuoluo Capsule on the basis of the control group. The recovery of ACR20,ACR50 and adverse reactions were compared between the two groups at 4 and 16 weeks of treatment. Results The improvement rate of the combined group was 80.43%,which was significantly higher than that of the control group (P<0.05). The rate of ACR20 reaching the standard for 4 weeks and the rate of ACR50 reaching the standard for 16 weeks in the combined group were higher than those in the control group,and the difference was statistically significant (P<0.05). There were no serious adverse reactions in both groups. Conclusion The combination of Heiguteng Zhuifenghuoluo Capsule and methotrexate can effectively control the progress of patients with rheumatoid arthritis,improve the symptoms of patients,and the curative effect is safe and reliable,which is worthy of promotion.
作者
董元凤
董春花
Dong Yuanfeng;Dong Chunhua(The Employee Medical Insurance of Fuzhou City,Fuzhou,Jiangxi 344000;The Traditional Chinese Medicine Hospital of Fuzhou City,Fuzhou,Jiangxi 344000)
出处
《基层医学论坛》
2019年第23期3267-3269,共3页
The Medical Forum
基金
抚州市指导性科技计划项目(抚科计字[2018]20号,第6号)